Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $146.2 million.

  • Xeris Biopharma Holdings' Non-Current Assets fell 7.66% to $146.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.2 million, marking a year-over-year decrease of 7.66%. This contributed to the annual value of $155.4 million for FY2024, which is 6.58% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Non-Current Assets stood at $146.2 million for Q3 2025, which was down 1.97% from $149.1 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Non-Current Assets peaked at $173.0 million during Q2 2023, and registered a low of $6.9 million during Q3 2021.
  • Its 3-year average for Non-Current Assets is $159.1 million, with a median of $158.3 million in 2024.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Non-Current Assets surged by 2,231.24% in 2021, and later decreased by 7.66% in 2025.
  • Xeris Biopharma Holdings' Non-Current Assets (Quarterly) stood at $161.8 million in 2021, then fell by 2.51% to $157.7 million in 2022, then climbed by 5.47% to $166.3 million in 2023, then fell by 6.58% to $155.4 million in 2024, then fell by 7.66% to $146.2 million in 2025.
  • Its last three reported values are $146.2 million in Q3 2025, $149.1 million for Q2 2025, and $152.0 million during Q1 2025.